{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T23:41:59Z","timestamp":1763768519631,"version":"3.45.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thoracic.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Surgery Clinics"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.thorsurg.2025.09.005","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:44:06Z","timestamp":1760543046000},"page":"99-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in Systemic Therapy for Lung Cancer"],"prefix":"10.1016","volume":"36","author":[{"given":"Mumtu","family":"Lalla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ethan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Jokic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyein","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balazs","family":"Halmos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thorsurg.2025.09.005_bib1","doi-asserted-by":"crossref","first-page":"102179","DOI":"10.1016\/j.ctrv.2021.102179","article-title":"Immunotherapy in non-small cell lung cancer harbouring driver mutations","volume":"96","author":"Addeo","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.thorsurg.2025.09.005_bib2","first-page":"1","article-title":"Non-small cell lung cancer, version 3.2025, NCCN clinical practice guidelines in oncology","author":"Riely","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.thorsurg.2025.09.005_bib3","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.thorsurg.2025.09.005_bib4","first-page":"100767","article-title":"The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy","volume":"37","author":"Proulx-Rocray","year":"2023","journal-title":"Cancer Treat Res Commun"},{"issue":"15_suppl","key":"10.1016\/j.thorsurg.2025.09.005_bib5","doi-asserted-by":"crossref","first-page":"9082","DOI":"10.1200\/JCO.2019.37.15_suppl.9082","article-title":"Impact of KRAS allele subtypes and concurrent genomic alterations on clinical outcomes to programmed death 1 axis blockade in non-small cell lung cancer","volume":"37","author":"Ricciuti","year":"2019","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.thorsurg.2025.09.005_bib6","doi-asserted-by":"crossref","first-page":"9019","DOI":"10.1200\/JCO.2016.34.15_suppl.9019","article-title":"Association of outcomes and co-occurring genomic alterations in patients with KRAS-mutant non-small cell lung cancer","volume":"34","author":"Riely","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.thorsurg.2025.09.005_bib7","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.jtho.2022.07.073","article-title":"OA15.04 Association Between KRAS\/STK11\/KEAP1 Mutations and Outcomes in POSEIDON: Durvalumab \u00b1 tremelimumab + Chemotherapy in mNSCLC","volume":"17","author":"Peters","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"16_suppl","key":"10.1016\/j.thorsurg.2025.09.005_bib8","doi-asserted-by":"crossref","first-page":"TPS8655","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS8655","article-title":"TRITON: phase 3b study of tremelimumab (T) + durvalumab (D) vs pembrolizumab (P), in combination with chemotherapy (CT), in non-squamous (NSQ) metastatic NSCLC (mNSCLC) with STK11 and\/or KEAP1 and\/or KRAS mutations","volume":"42","author":"Skoulidis","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.thorsurg.2025.09.005_bib9","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.lungcan.2019.10.021","article-title":"Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib","volume":"141","author":"Zhao","year":"2020","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.thorsurg.2025.09.005_bib10","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.annonc.2024.05.541","article-title":"Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA","volume":"35","author":"Felip","year":"2024","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.thorsurg.2025.09.005_bib11","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.jtho.2024.09.184","article-title":"MA12.03 FLAURA2: resistance, and Impact of baseline TP53 Alterations in patients treated with 1L osimertinib \u00b1 platinum-pemetrexed","volume":"19","author":"Yang","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.thorsurg.2025.09.005_bib12","doi-asserted-by":"crossref","first-page":"e006397","DOI":"10.1136\/jitc-2022-006397","article-title":"Next-generation ctDNA-driven clinical trials in precision immuno-oncology","volume":"11","author":"Aggarwal","year":"2023","journal-title":"J ImmunoTherapy Cancer"},{"issue":"1","key":"10.1016\/j.thorsurg.2025.09.005_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00054","article-title":"Circulating Tumor DNA in Non\u2013Small-Cell Lung Cancer: A Primer for the Clinician","author":"Singh","year":"2017","journal-title":"JCO Precision Oncology"},{"issue":"7_Supplement","key":"10.1016\/j.thorsurg.2025.09.005_bib14","doi-asserted-by":"crossref","first-page":"CT017","DOI":"10.1158\/1538-7445.AM2024-CT017","article-title":"Abstract CT017: FLAURA2: exploratory analysis of baseline (BL) and on-treatment plasma EGFRm dynamics in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) \u00b1 platinum-pemetrexed","volume":"84","author":"J\u00e4nne","year":"2024","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.thorsurg.2025.09.005_bib15","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1038\/s41591-023-02598-9","article-title":"ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results","volume":"29","author":"Anagnostou","year":"2023","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.thorsurg.2025.09.005_bib16","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.pccm.2023.04.001","article-title":"Circulating tumor DNA (ctDNA)-based minimal residual disease in non-small cell lung cancer","volume":"1","author":"Tang","year":"2023","journal-title":"Chin Med J Pulm Crit Care Med"},{"issue":"6","key":"10.1016\/j.thorsurg.2025.09.005_bib17","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/s41591-025-03577-y","article-title":"Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB\u2013IIIA non-small-cell lung cancer","volume":"31","author":"Herbst","year":"2025","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.thorsurg.2025.09.005_bib18","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thorsurg.2025.09.005_bib19","doi-asserted-by":"crossref","first-page":"S994","DOI":"10.1016\/j.annonc.2022.07.1103","article-title":"975P Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial","volume":"33","author":"Smit","year":"2022","journal-title":"Ann Oncology"},{"key":"10.1016\/j.thorsurg.2025.09.005_bib20","unstructured":"U.S. Food and Drug Administration. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors. U.S. Food & Drug Administration. 2024. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2."},{"issue":"25","key":"10.1016\/j.thorsurg.2025.09.005_bib21","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.24.00720","article-title":"Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein-overexpressing advanced Nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY trial","volume":"42","author":"Camidge","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.thorsurg.2025.09.005_bib22","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.annonc.2025.01.001","article-title":"Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced\/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib","volume":"36","author":"Horinouchi","year":"2025","journal-title":"Ann Oncol"},{"journal-title":"U.S. Food & Drug Administration","article-title":"FDA grants accelerated approval to telisotuzumab vedotin-tllv for NSCLC with high c-Met protein overexpression","year":"2025","key":"10.1016\/j.thorsurg.2025.09.005_bib23"},{"issue":"16_suppl","key":"10.1016\/j.thorsurg.2025.09.005_bib24","doi-asserted-by":"crossref","first-page":"9013","DOI":"10.1200\/JCO.2023.41.16_suppl.9013","article-title":"Predictive biomarkers for treatment with amivantamab plus lazertinib among EGFR-mutated NSCLC in the post-osimertinib setting: analysis of tissue IHC and ctDNA NGS","volume":"41","author":"Besse","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.thorsurg.2025.09.005_bib25","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jtho.2024.09.015","article-title":"PL02.11 normalized membrane ratio of TROP2 by quantitative continuous scoring is predictive of clinical outcomes in TROPION-lung 01","volume":"19","author":"Garassino","year":"2024","journal-title":"J Thoracic Oncology"},{"issue":"6","key":"10.1016\/j.thorsurg.2025.09.005_bib26","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1016\/j.cllc.2024.06.011","article-title":"Impact of PROphet test in changing physicians\u2019 therapeutic decision-making for checkpoint immunotherapy in non-small-cell lung cancer","volume":"25","author":"Gandara","year":"2024","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"10.1016\/j.thorsurg.2025.09.005_bib27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1001\/jamaoncol.2024.5356","article-title":"Deep learning model for predicting immunotherapy response in advanced non-small cell lung cancer","volume":"11","author":"Rakaee","year":"2025","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.thorsurg.2025.09.005_bib28","doi-asserted-by":"crossref","first-page":"31382","DOI":"10.1038\/s41598-024-82903-9","article-title":"Optimizing T cell inflamed signature through a combination biomarker approach for predicting immunotherapy response in NSCLC","volume":"14","author":"Chen","year":"2024","journal-title":"Scientific Reports"},{"issue":"1","key":"10.1016\/j.thorsurg.2025.09.005_bib29","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40364-024-00566-0","article-title":"Oncogenic alterations in advanced NSCLC: a molecular super-highway","volume":"12","author":"Friedlaender","year":"2024","journal-title":"Biomark Res"},{"issue":"3","key":"10.1016\/j.thorsurg.2025.09.005_bib30","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.ijrobp.2003.09.093","article-title":"The HER receptor family: a rich target for therapeutic development","volume":"58","author":"Mass","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.thorsurg.2025.09.005_bib31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40291-021-00563-1","article-title":"Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer: a Meta-analysis","volume":"26","author":"Melosky","year":"2022","journal-title":"Mol Diagn Ther"},{"issue":"10","key":"10.1016\/j.thorsurg.2025.09.005_bib32","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.thorsurg.2025.09.005_bib33","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.thorsurg.2025.09.005_bib34","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.thorsurg.2025.09.005_bib35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.thorsurg.2025.09.005_bib36","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.thorsurg.2025.09.005_bib37","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jtho.2022.11.022","article-title":"Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers","volume":"18","author":"Choudhury","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.thorsurg.2025.09.005_bib38","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.lungcan.2022.05.011","article-title":"Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: focus on novel therapies","volume":"170","author":"Johnson","year":"2022","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.thorsurg.2025.09.005_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030612","article-title":"MET Amplification as a resistance driver to TKI Therapies in lung cancer: clinical challenges and opportunities","volume":"15","author":"Qin","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.thorsurg.2025.09.005_bib40","doi-asserted-by":"crossref","first-page":"S469","DOI":"10.1016\/j.jtho.2022.07.823","article-title":"EP08.02-140 MET biomarker-based preliminary efficacy analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC post-osimertinib","volume":"17","author":"Ahn","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"8","key":"10.1016\/j.thorsurg.2025.09.005_bib41","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(24)00270-5","article-title":"Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial","volume":"25","author":"Wu","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.thorsurg.2025.09.005_bib42","doi-asserted-by":"crossref","first-page":"S978","DOI":"10.1016\/j.annonc.2021.08.1844","article-title":"1239P ORCHARD osimertinib + savolitinib interim analysis: a biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib","volume":"32","author":"Yu","year":"2021","journal-title":"Ann Oncol"},{"issue":"17_suppl","key":"10.1016\/j.thorsurg.2025.09.005_bib43","doi-asserted-by":"crossref","first-page":"LBA8505","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA8505","volume":"43","author":"Lu","year":"2025","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.thorsurg.2025.09.005_bib44","first-page":"S468","article-title":"EP08.02-138 SAFFRON: Ph3 savolitinib + Osimertinib vs Chemotherapy in EGFRm NSCLC with MET overexpression\/amplification post-osimertinib","volume":"17","author":"Lu","year":"2022","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.thorsurg.2025.09.005_bib45","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thorsurg.2025.09.005_bib46","first-page":"9","article-title":"4O First-line (1L) osimertinib (osi) \u00b1 platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: FLAURA2 post-progression outcomes","author":"Valdiviezo","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.thorsurg.2025.09.005_bib47","doi-asserted-by":"crossref","first-page":"S1311","DOI":"10.1016\/j.annonc.2023.10.069","article-title":"LBA68 FLAURA2: safety and CNS outcomes of first-line (1L) osimertinib (osi) \u00b1 chemotherapy (CTx) in EGFRm advanced NSCLC","volume":"34","author":"Planchard","year":"2023","journal-title":"Ann Oncol"},{"issue":"29","key":"10.1016\/j.thorsurg.2025.09.005_bib48","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.thorsurg.2025.09.005_bib49","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.thorsurg.2025.09.005_bib101","first-page":"1234","article-title":"Phase II dose-randomized study of sunvozertinib in platinum-pretreated non\u2013small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations (WU-KONG1B)","volume":"25","author":"Yang","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10089","key":"10.1016\/j.thorsurg.2025.09.005_bib50","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.thorsurg.2025.09.005_bib51","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: Final results of phase 3 ALTA-1L trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"21","key":"10.1016\/j.thorsurg.2025.09.005_bib52","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line Lorlatinib or Crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J med"},{"issue":"2","key":"10.1016\/j.thorsurg.2025.09.005_bib53","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1470-2045(19)30690-4","article-title":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials","volume":"21","author":"Drilon","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.thorsurg.2025.09.005_bib54","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2302299","article-title":"Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer","volume":"390","author":"Drilon","year":"2024","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.thorsurg.2025.09.005_bib102","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1200\/JCO-25-00275","article-title":"Taletrectinib in ROS1+ non\u2013small cell lung cancer: TRUST","volume":"43","author":"P\u00e9rol","year":"2025","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.thorsurg.2025.09.005_bib55","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.thorsurg.2025.09.005_bib56","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.thorsurg.2025.09.005_bib57","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","article-title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study","volume":"22","author":"Gainor","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.thorsurg.2025.09.005_bib58","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.thorsurg.2025.09.005_bib59","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.thorsurg.2025.09.005_bib60","doi-asserted-by":"crossref","first-page":"105110","DOI":"10.1016\/j.esmoop.2025.105110","article-title":"Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer","volume":"10","author":"Hong","year":"2025","journal-title":"ESMO Open"},{"issue":"23","key":"10.1016\/j.thorsurg.2025.09.005_bib103","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1056\/NEJMoa2503704","article-title":"Zongertinib in previously treated HER2-mutant non-small-cell lung cancer","volume":"392","author":"Heymach","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thorsurg.2025.09.005_bib61","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.ijbiomac.2020.11.058","article-title":"Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: recent advances and clinical trials","volume":"167","author":"Hosseini","year":"2021","journal-title":"Int J Biol Macromol"},{"issue":"10","key":"10.1016\/j.thorsurg.2025.09.005_bib62","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1038\/s41591-023-02554-7","article-title":"Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial","volume":"29","author":"Cho","year":"2023","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.thorsurg.2025.09.005_bib63","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S1556-0864(25)00199-6","article-title":"4O: Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: Final overall survival (OS) from the phase III MARIPOSA study","volume":"20","author":"Yang","year":"2025","journal-title":"J Thoracic Oncol"},{"issue":"30","key":"10.1016\/j.thorsurg.2025.09.005_bib64","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1200\/JCO.24.01001","article-title":"Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory epidermal growth factor receptor-mutated non-small cell lung cancer: primary results from the phase III PALOMA-3 study","volume":"42","author":"Leighl","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.thorsurg.2025.09.005_bib65","doi-asserted-by":"crossref","first-page":"S1245","DOI":"10.1016\/j.annonc.2024.08.2297","article-title":"LBA55 Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA study","volume":"35","author":"Besse","year":"2024","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.thorsurg.2025.09.005_bib66","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.thorsurg.2025.09.005_bib67","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa2405008","article-title":"Efficacy of Zenocutuzumab in NRG1 fusion-positive cancer","volume":"392","author":"Schram","year":"2025","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.thorsurg.2025.09.005_bib68","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/jjco\/hyad052","article-title":"Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance","volume":"53","author":"Araki","year":"2023","journal-title":"Jpn J Clin Oncol"},{"issue":"8","key":"10.1016\/j.thorsurg.2025.09.005_bib69","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/oncolo\/oyae151","article-title":"FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations","volume":"29","author":"Mehta","year":"2024","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.thorsurg.2025.09.005_bib70","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/S1556-0864(25)00319-3","volume":"20","author":"Nadal","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"16_suppl","key":"10.1016\/j.thorsurg.2025.09.005_bib71","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.2025.43.16_suppl.3000","article-title":"DB-1310, a HER3-targeted ADC, in pts with advanced solid tumors: Preliminary results from the phase 1\/2a trial","volume":"43","author":"Lisberg","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.thorsurg.2025.09.005_bib72","doi-asserted-by":"crossref","first-page":"8506","DOI":"10.1200\/JCO.2025.43.16_suppl.8506","article-title":"Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study","volume":"43","author":"Mok","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.thorsurg.2025.09.005_bib73","doi-asserted-by":"crossref","first-page":"1380584","DOI":"10.3389\/fonc.2024.1380584","article-title":"KRAS G12C inhibitor combination therapies: current evidence and challenge","volume":"14","author":"Miyashita","year":"2024","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.thorsurg.2025.09.005_bib74","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","article-title":"KRAS inhibitors: resistance drivers and combinatorial strategies","volume":"11","author":"Isermann","year":"2025","journal-title":"Trends Cancer"},{"issue":"7","key":"10.1016\/j.thorsurg.2025.09.005_bib75","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1158\/2159-8290.CD-22-1420","article-title":"Comutations and KRASG12C inhibitor Efficacy in advanced NSCLC","volume":"13","author":"Negrao","year":"2023","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.thorsurg.2025.09.005_bib76","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung cancer Harboring a KRAS(G12C) mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.thorsurg.2025.09.005_bib77","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"issue":"10378","key":"10.1016\/j.thorsurg.2025.09.005_bib78","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"de Langen","year":"2023","journal-title":"Lancet"},{"issue":"16_suppl","key":"10.1016\/j.thorsurg.2025.09.005_bib79","doi-asserted-by":"crossref","first-page":"8500","DOI":"10.1200\/JCO.2025.43.16_suppl.8500","article-title":"First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced\/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study","volume":"43","author":"J\u00e4nne","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10183","key":"10.1016\/j.thorsurg.2025.09.005_bib80","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.thorsurg.2025.09.005_bib81","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.thorsurg.2025.09.005_bib82","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.thorsurg.2025.09.005_bib83","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J med"},{"issue":"10274","key":"10.1016\/j.thorsurg.2025.09.005_bib84","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.thorsurg.2025.09.005_bib85","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jtho.2024.03.002","article-title":"Precision immunotherapy for STK11\/KEAP1-mutant NSCLC","volume":"19","author":"Ricciuti","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"8038","key":"10.1016\/j.thorsurg.2025.09.005_bib86","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41586-024-07943-7","article-title":"CTLA4 blockade abrogates KEAP1\/STK11-related resistance to PD-(L)1 inhibitors","volume":"635","author":"Skoulidis","year":"2024","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.thorsurg.2025.09.005_bib87","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.thorsurg.2025.09.005_bib88","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.thorsurg.2025.09.005_bib89","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1200\/JCO.22.00975","article-title":"Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study","volume":"41","author":"Johnson","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.thorsurg.2025.09.005_bib90","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thorsurg.2025.09.005_bib91","doi-asserted-by":"crossref","first-page":"S1243","DOI":"10.1016\/j.annonc.2024.08.2295","article-title":"LBA53 Nivolumab (NIVO) plus relatlimab with platinum-doublet chemotherapy (PDCT) vs NIVO + PDCT as first-line (1L) treatment (tx) for stage IV or recurrent NSCLC: Results from the randomized phase II RELATIVITY-104 study","volume":"35","author":"Girard","year":"2024","journal-title":"Ann Oncol"},{"issue":"12_Supplement","key":"10.1016\/j.thorsurg.2025.09.005_bib92","doi-asserted-by":"crossref","first-page":"B123","DOI":"10.1158\/1535-7163.TARG-23-B123","article-title":"Abstract B123: mechanism of action of ivonescimab (AK112\/SMT112): a first-in-class tetravalent Fc-silent bispecific antibody with dual blockade of PD-1 and VEGF that promotes cooperative biological effects","volume":"22","author":"Zhong","year":"2023","journal-title":"Mol Cancer Ther"},{"issue":"10481","key":"10.1016\/j.thorsurg.2025.09.005_bib93","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(24)02722-3","article-title":"Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China","volume":"405","author":"Xiong","year":"2025","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.thorsurg.2025.09.005_bib94","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/jama.2024.10613","article-title":"Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: a randomized clinical trial","volume":"332","author":"Fang","year":"2024","journal-title":"JAMA"},{"issue":"10427","key":"10.1016\/j.thorsurg.2025.09.005_bib95","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.thorsurg.2025.09.005_bib96","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.22.02186","article-title":"Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: Updated results from the phase III randomized ADAURA trial","volume":"41","author":"Herbst","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.thorsurg.2025.09.005_bib97","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.thorsurg.2025.09.005_bib98","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non-small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.thorsurg.2025.09.005_bib99","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"issue":"10459","key":"10.1016\/j.thorsurg.2025.09.005_bib100","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet"}],"container-title":["Thoracic Surgery Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547412725000751?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547412725000751?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T23:38:33Z","timestamp":1763768313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1547412725000751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":103,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1547412725000751"],"URL":"https:\/\/doi.org\/10.1016\/j.thorsurg.2025.09.005","relation":{},"ISSN":["1547-4127"],"issn-type":[{"type":"print","value":"1547-4127"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in Systemic Therapy for Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Thoracic Surgery Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thorsurg.2025.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}